Can Celltrion’s Eydenzelt disrupt Canada’s aflibercept market after Health Canada approval?

Celltrion, Inc., the South Korean biopharmaceutical company known for its aggressive biosimilar expansion strategy, has announced that Health Canada has granted regulatory approval to Eydenzelt, a biosimilar referencing Eylea (aflibercept 2mg). The regulatory clearance covers all indications for which Eylea is currently approved in Canada, including neovascular age-related macular degeneration, diabetic macular edema, and other retinal diseases. This approval enables Celltrion to enter a highly lucrative ophthalmology market segment in Canada, where aflibercept therapies command significant payer budgets and specialist demand.

Eydenzelt has been approved in both vial and pre-filled syringe formats, offering flexibility for ophthalmologists in administration. It is the first biosimilar from Celltrion in the Canadian ophthalmology domain and joins an expanding global portfolio of biosimilar assets aimed at high-value biologics. Celltrion has previously secured regulatory clearance for Eydenzelt in both the United States and the European Union, with the U.S. Food and Drug Administration granting its approval in October 2025 and the European Commission giving its nod earlier in February.

The milestone approval adds to Celltrion’s momentum in Canada, where it now has ten approved biosimilars covering eight different biologic molecules. According to executives, the company aims to consolidate its Canadian operations by strengthening market access and leveraging its in-house manufacturing infrastructure to deliver cost-effective therapeutic alternatives across specialty care areas.

What clinical data supported the approval of Eydenzelt in Canada?

The decision by Health Canada was based on a comprehensive review of what regulators described as the “totality of evidence,” encompassing analytical similarity, nonclinical pharmacology, and clinical comparability studies. Central to the clinical submission was a randomized, double-masked, parallel-group, global Phase III trial that enrolled 348 patients diagnosed with diabetic macular edema. The study directly compared Eydenzelt to the reference product, Eylea, over a 52-week period.

The primary endpoint in the trial was the change in best-corrected visual acuity at Week 8, a widely recognized outcome measure in ophthalmology clinical development. Eydenzelt successfully met the pre-defined equivalence margin for this endpoint. Secondary metrics assessing safety, pharmacokinetics, and immunogenicity were also reported to be in line with the reference drug, thereby confirming biosimilarity in both therapeutic effect and biological response.

The strong equivalence data was critical not just for the Canadian market but also to position Eydenzelt competitively on the global stage as aflibercept biosimilars begin to erode the exclusivity of reference brands.

How does this approval fit into Celltrion’s broader biosimilar strategy in Canada?

The launch of Eydenzelt marks Celltrion’s formal entry into the Canadian ophthalmology sector, a move that aligns with its ambition to capture greater share in biologics with high treatment costs and limited biosimilar penetration. Prior to this, Celltrion Healthcare Canada has focused largely on immunology, oncology, and chronic autoimmune diseases, with approved products including Remsima (infliximab), Yuflyma (adalimumab), Vegzelma (bevacizumab), and Avtozma (tocilizumab).

Jungyong Shin, Managing Director of Celltrion Healthcare Canada, stated that the Health Canada approval serves as a foundation for expanding into new therapeutic segments. He noted that the company will rely on its globally integrated research and development ecosystem and its mammalian cell culture manufacturing capabilities to improve patient access to high-quality biosimilars.

Eydenzelt’s approval also aligns with growing interest from Canadian policymakers and payers in expanding biosimilar usage across specialty drug categories. Provinces such as British Columbia and Ontario have already taken steps to promote biosimilar switching in rheumatology and oncology, and analysts expect similar momentum to build in ophthalmology, where high injection costs burden public and private insurance systems alike.

Why are aflibercept biosimilars gaining traction globally in 2025?

Aflibercept, originally developed by Regeneron Pharmaceuticals and marketed globally through partnerships including Bayer AG, has been a cornerstone in the treatment of retinal vascular diseases. The molecule works as a vascular endothelial growth factor (VEGF) inhibitor and has become a staple in treating wet age-related macular degeneration, diabetic eye disease, and retinal vein occlusion. Global sales of Eylea exceeded $9 billion in recent years, placing it among the most valuable biologics in ophthalmology.

With its patents now expiring across major geographies, aflibercept is viewed as a high-priority biosimilar target for biopharmaceutical companies. Industry observers believe that Celltrion, with its deep biologics pipeline and proven regulatory track record, is well-positioned to be among the first wave of players to capture market share from Eylea, particularly in systems where biosimilar adoption is backed by policy incentives.

However, unlike biosimilars in rheumatology or oncology, biosimilar adoption in ophthalmology faces more structural hurdles. These include practitioner conservatism, training needs for new injectables, and the close monitoring required for retinal disease outcomes. Analysts suggest that Celltrion’s success will depend not just on price competition but also on strategic engagement with key opinion leaders and provincial drug programs.

What does this mean for Celltrion’s Canadian market presence going forward?

With ten biosimilars now approved by Health Canada, Celltrion Healthcare Canada has established a strong foundation for long-term commercial operations. The company’s product mix spans both hospital-administered and retail-distributed biologics, enabling it to participate in multiple procurement models within Canada’s fragmented healthcare landscape.

Celltrion’s next challenge lies in ensuring that Eydenzelt achieves real-world market penetration. This will depend on provincial reimbursement decisions, ophthalmologist familiarity, and patient transition programs. Pricing strategy will also be critical, especially as Canadian biosimilar pricing tends to settle significantly below originator benchmarks due to reference pricing and tender-based contracting.

Market intelligence firms tracking the sector believe that Celltrion’s vertically integrated operations, coupled with its global manufacturing scale, could give it an edge in negotiating long-term supply agreements and market access partnerships across Canada. Investors will likely monitor upcoming public formulary inclusions, as well as any patient assistance or switching programs designed to accelerate uptake.

For Celltrion, the approval of Eydenzelt represents not just a product milestone but a strategic advance in diversifying its biosimilar revenue streams beyond inflammatory diseases and oncology into high-volume specialty care categories.

What are the key takeaways from the Health Canada approval of Celltrion’s Eydenzelt?

Health Canada’s authorization of Eydenzelt offers Celltrion a gateway into the Canadian ophthalmology sector. The regulatory nod affirms the product’s clinical comparability to Eylea across all indications and provides a new revenue opportunity in one of the costliest biologic categories in Canadian healthcare. The approval also enhances Celltrion Healthcare Canada’s biosimilar portfolio to ten products, with momentum building for broader adoption across public and private payers.

Celltrion will now look to translate this regulatory success into commercial traction by targeting formulary inclusion, clinical endorsement, and patient switching in a market still adapting to biosimilar integration. Analysts expect that this move, if executed strategically, could serve as a template for future ophthalmic biosimilar rollouts in other developed markets.

What are the key takeaways from Celltrion’s Health Canada approval of Eydenzelt?

• Health Canada approved Eydenzelt, Celltrion’s biosimilar referencing aflibercept (Eylea), for all current Canadian Eylea indications including age-related macular degeneration and diabetic macular edema.

• The approval was supported by a global Phase III trial involving 348 patients with diabetic macular edema, where Eydenzelt met efficacy and safety equivalence benchmarks compared to Eylea.

• Eydenzelt is Celltrion’s first ophthalmology biosimilar approved in Canada and marks its entry into the high-value Canadian eye care biologics market.

• The product will be offered in both vial and pre-filled syringe formats, targeting flexibility for ophthalmologists administering intravitreal injections.

• Celltrion now has ten biosimilar products approved by Health Canada, extending its reach across immunology, oncology, and now ophthalmology.

• Canadian biosimilar adoption in ophthalmology remains in early stages, but analysts believe cost pressures and provincial policies could accelerate uptake.

• The aflibercept biosimilar space is becoming increasingly competitive globally, with Celltrion joining other major players targeting the multibillion-dollar Eylea market.

• Celltrion aims to leverage its integrated manufacturing and R&D model to strengthen commercial execution and negotiate payer access in Canada.

• Analysts view the approval as a strategic move to diversify revenue streams and build long-term presence in a segment with high barriers to biosimilar entry.

• The company’s near-term focus will likely be on provincial formulary inclusion, ophthalmologist engagement, and switching programs to capture share from Eylea.